Session Chair Profile

Ph.D., MBA, CEO, Maze Therapeutics

Biography
Dr. Jason Coloma is the CEO of Maze Therapeutics. Prior to his appointment to CEO, he was a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of the company. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Jason holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.


 Session Abstract – PMWC 2023 Silicon Valley

Track 1 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: Sharon Benzeno, Adaptive Biotechnologies

  • PMWC 2023 Luminary Award Ceremony
    Honoree: Bruce Levine, University of Pennsylvania
  • Advance and Optimize Cell Therapies in Oncology (PANEL)
    Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Ira Mellman, Genenetch
    - Lewis “Rusty” Williams, Walking Fish Therapeutics
    - Loïc VINCENT, Affini-T Therapeutics
    - Nick Haining, Arsenal
  • Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
    Chair: Carl June, UPenn
    - Lenny Dragone, Sonoma
    - James Chung, Kyverna
    - David Chang, Cabaletta
    - Cristina Musselli, Abata Therapeutics
  • Innovations in Cell Therapy Manufacturing (PANEL)
    Chair: Bruce Levine, University of Pennsylvania
    - Chris Holt, BMS
    - Heidi Hagen, Sonoma Bio
    - Rahul Singhvi, Resilience
    - Snehal Patel, Sana Biotechnology
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
    Chair: Jason Coloma, Maze Therapeutics
    - Peter DiLaura, Sonoma Bio
    - Nick Haining, Arsenal
    - Ulrik Nielsen, Sanofi
    - Lacey Padron, Parker Institute